Cargando…

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism

Single nucleotide polymorphisms (SNPs) reportedly influence the effect of nivolumab in metastatic renal cell carcinoma (mRCC). This study aimed to evaluate the relationship between the clinical outcomes of patients with mRCC and SNPs in programmed cell death protein 1 (PD-1) protein-coding gene (PDC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Mizuki, Numakura, Kazuyuki, Hatakeyama, Shingo, Muto, Yumina, Sekine, Yuya, Sasagawa, Hajime, Kashima, Soki, Yamamoto, Ryohei, Koizumi, Atsushi, Nara, Taketoshi, Saito, Mitsuru, Narita, Shintaro, Ohyama, Chikara, Habuchi, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324515/
https://www.ncbi.nlm.nih.gov/pubmed/35885987
http://dx.doi.org/10.3390/genes13071204
_version_ 1784756826203488256
author Kobayashi, Mizuki
Numakura, Kazuyuki
Hatakeyama, Shingo
Muto, Yumina
Sekine, Yuya
Sasagawa, Hajime
Kashima, Soki
Yamamoto, Ryohei
Koizumi, Atsushi
Nara, Taketoshi
Saito, Mitsuru
Narita, Shintaro
Ohyama, Chikara
Habuchi, Tomonori
author_facet Kobayashi, Mizuki
Numakura, Kazuyuki
Hatakeyama, Shingo
Muto, Yumina
Sekine, Yuya
Sasagawa, Hajime
Kashima, Soki
Yamamoto, Ryohei
Koizumi, Atsushi
Nara, Taketoshi
Saito, Mitsuru
Narita, Shintaro
Ohyama, Chikara
Habuchi, Tomonori
author_sort Kobayashi, Mizuki
collection PubMed
description Single nucleotide polymorphisms (SNPs) reportedly influence the effect of nivolumab in metastatic renal cell carcinoma (mRCC). This study aimed to evaluate the relationship between the clinical outcomes of patients with mRCC and SNPs in programmed cell death protein 1 (PD-1) protein-coding gene (PDCD1) and explore any potential correlation with patient prognosis and incidence of immune-related adverse events (irAEs). In total, 106 patients with mRCC, who were treated with nivolumab alone (n = 59) or nivolumab and ipilimumab (n = 47), were enrolled in the study. Three SNPs in the PDCD1 gene, namely PD-1.3, PD-1.5, and PD-1.6, were assessed. Patients harboring the PD-1.6 G allele experienced more severe (odds ratio, 3.390; 95% confidence interval 1.517–7.756; p = 0.003) and multiple (OR, 2.778; 95% CI, 1.020–6.993 p = 0.031) irAEs than those harboring the AA genotype. Thus, the existence of the PDCD1 PD-1.6 polymorphism (G allele) was associated with the occurrence of severe and multiple irAEs in patients with mRCC. Further evaluation of PDCD1 polymorphisms might help identify patients experiencing irAE by nivolumab treatment.
format Online
Article
Text
id pubmed-9324515
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93245152022-07-27 Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism Kobayashi, Mizuki Numakura, Kazuyuki Hatakeyama, Shingo Muto, Yumina Sekine, Yuya Sasagawa, Hajime Kashima, Soki Yamamoto, Ryohei Koizumi, Atsushi Nara, Taketoshi Saito, Mitsuru Narita, Shintaro Ohyama, Chikara Habuchi, Tomonori Genes (Basel) Article Single nucleotide polymorphisms (SNPs) reportedly influence the effect of nivolumab in metastatic renal cell carcinoma (mRCC). This study aimed to evaluate the relationship between the clinical outcomes of patients with mRCC and SNPs in programmed cell death protein 1 (PD-1) protein-coding gene (PDCD1) and explore any potential correlation with patient prognosis and incidence of immune-related adverse events (irAEs). In total, 106 patients with mRCC, who were treated with nivolumab alone (n = 59) or nivolumab and ipilimumab (n = 47), were enrolled in the study. Three SNPs in the PDCD1 gene, namely PD-1.3, PD-1.5, and PD-1.6, were assessed. Patients harboring the PD-1.6 G allele experienced more severe (odds ratio, 3.390; 95% confidence interval 1.517–7.756; p = 0.003) and multiple (OR, 2.778; 95% CI, 1.020–6.993 p = 0.031) irAEs than those harboring the AA genotype. Thus, the existence of the PDCD1 PD-1.6 polymorphism (G allele) was associated with the occurrence of severe and multiple irAEs in patients with mRCC. Further evaluation of PDCD1 polymorphisms might help identify patients experiencing irAE by nivolumab treatment. MDPI 2022-07-05 /pmc/articles/PMC9324515/ /pubmed/35885987 http://dx.doi.org/10.3390/genes13071204 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kobayashi, Mizuki
Numakura, Kazuyuki
Hatakeyama, Shingo
Muto, Yumina
Sekine, Yuya
Sasagawa, Hajime
Kashima, Soki
Yamamoto, Ryohei
Koizumi, Atsushi
Nara, Taketoshi
Saito, Mitsuru
Narita, Shintaro
Ohyama, Chikara
Habuchi, Tomonori
Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
title Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
title_full Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
title_fullStr Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
title_full_unstemmed Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
title_short Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
title_sort severe immune-related adverse events in patients treated with nivolumab for metastatic renal cell carcinoma are associated with pdcd1 polymorphism
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324515/
https://www.ncbi.nlm.nih.gov/pubmed/35885987
http://dx.doi.org/10.3390/genes13071204
work_keys_str_mv AT kobayashimizuki severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT numakurakazuyuki severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT hatakeyamashingo severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT mutoyumina severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT sekineyuya severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT sasagawahajime severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT kashimasoki severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT yamamotoryohei severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT koizumiatsushi severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT narataketoshi severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT saitomitsuru severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT naritashintaro severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT ohyamachikara severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism
AT habuchitomonori severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism